Christopher Bunick, MD, PhD, is a physician-scientist practicing general medical and surgical dermatology at Yale Dermatology, and is an associate professor of dermatology at the Yale School of Medicine.
Molecular Differentiation of Dermatologic Therapeutics With Christopher Bunick, MD, PhD
Bunick presented 3 sessions at the 2023 World Congress of Dermatology meeting in Singapore.
Christopher Bunick, MD, PhD, Reviews Crucial Discussion of Biologics for AD and More
Bunick spoke at the Fall Clinical Dermatology Conference for PAs and NPs to discuss important considerations of biologics use for atopic dermatitis management.
Christopher Bunick, MD, PhD, Discusses Benzene Contamination in Personal Care Products and Why It Keeps Happening
Aerosolized dry shampoo is the latest personal care product to contain detectable levels of benzene, according to Bunick’s SCALE 2023 session.
Advances in Acne Management
Christopher Bunick, MD, PhD, comments on the role isotretinoin plays in his practice and comments on further advancements in the management of this condition.
Expert Insights into the Use of Isotretinoin
An expert in dermatology shares his opinion on oral versus topical acne treatment options and how to assess response to treatment.
Approaches to Target Sebum Production
Dr Christopher Bunick discusses the role the microbiome and sebum play in acne production and highlights the role Clascoterone cream 1% plays in targeting these agents.
Overview and Prevalence of Acne Vulgaris
Christopher Bunick, MD, PhD, provides an overview of acne vulgaris and the populations it impacts; highlighting that this is more than just an adolescent affliction and the role of sebum production.
Sun Protection is No Joke
Christopher Bunick, MD, PhD, shares pearls from his research in benzene contamination in sunscreens and what advice he shares with patients.
Christopher Bunick, MD, PhD, Discusses Late-Breaking Long-Term 4-Year Safety Data of Upadacitinib for AD
Bunick provides an overview of the most important highlights from his late-breaking session at RAD 2023.
Key Takeaways on the Management of Atopic Dermatitis
Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.
Ongoing Challenges in the Management of Atopic Dermatitis
Experts share insight on the challenges inherent in treating patients with atopic dermatitis despite recent advances in therapy.
Atopic Dermatitis: Practical Advice on Selecting and Using JAK Inhibitors
Concluding their focused discussion on JAK inhibitors in atopic dermatitis, panelists share advice on the optimal selection based on route of administration and use of these agents.
Recent Approval of Oral JAK Inhibitors for Atopic Dermatitis
A brief review of 2 oral JAK inhibitors recently approved for patients with atopic dermatitis.
Topical Ruxolitinib Use in Atopic Dermatitis
A panel of experts review the use of topical ruxolitinib in atopic dermatitis, shedding light on safety and efficacy considerations.
JAK Inhibitors in Atopic Dermatitis: Historical Use and Mechanisms of Action
Focusing on JAK inhibitors, panelists consider the historical use of these agents in atopic dermatitis and their corresponding mechanisms of action.
Treatment for Mild to Moderate vs Moderate to Severe Atopic Dermatitis
Experts define stages of atopic dermatitis and share insight on the conventional treatment landscape for mild to moderate and moderate to severe atopic dermatitis.
Atopic Dermatitis Overview: Pathophysiology, Diagnosis, and Burden
Expert perspectives on the nature of atopic dermatitis, ranging from diagnosis and pathophysiology to the clinical and social burden it places on patients.
Plaque Psoriasis Management: Future Directions in Care
Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.
Biologic Therapy in Plaque Psoriasis: Treating During the COVID-19 Pandemic
Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.
Unmet Needs in Moderate to Severe Plaque Psoriasis Management
A brief discussion on the unmet needs and ongoing challenges in the treatment of plaque psoriasis.
Plaque Psoriasis Patient Case 2: Factors in Selecting 2L Therapy
Shared insight on which factors are most important in determining second-line therapy for plaque psoriasis.
Plaque Psoriasis Patient Case 2: Switching Therapy at Treatment Failure
Moving on to the second patient case, panelists discuss switching therapy at treatment failure for plaque psoriasis.
Factors in Selecting Biologic Therapy for Moderate to Severe Plaque Psoriasis
Panelists share which factors they use to determine optimal therapy in the moderate to severe plaque psoriasis setting.
Plaque Psoriasis: Biologic Therapy Toxicity Profiles
A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.
Bimekizumab’s Potential in Moderate-to-Severe Plaque Psoriasis
A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.
Moderate to Severe Plaque Psoriasis: An Overview of Biologic Agents
A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.
Moderate to Severe Plaque Psoriasis: What is the Standard of Care?
Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.
Plaque Psoriasis Case 1: Selecting a Therapeutic Class
The panel reviews therapeutic classes and their respective benefits in patients being treated for plaque psoriasis.
Plaque Psoriasis Case 1: Patient Counseling and Approaching Therapy
Centering discussion on a case of plaque psoriasis, experts share their experience with patient counseling and selecting therapy.
Understanding the Psychosocial Burden of Plaque Psoriasis
Considerations for the psychological and social impact that plaque psoriasis may have on a patient.